Lysophosphatidylcholine 18:2 加剧了 Th17 主导炎症 在肥胖的喘中
Liting Cao1, Huan Liu1, Ying Shang1
1Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, 49 North Garden Road, Haidian District, Beijing, 100191, China.
Lysophosphatidylcholine (LPC) 18: 2 在肥胖喘中降低,并促进 Th17 炎症. 针对LPC 18:2路径可能为这种喘表型提供新的治疗方法.
科学领域:
- 免疫学 免疫学 免疫学
- 代谢过程中的代谢.
- 肺部病理学 肺部病理学
背景情况:
- 肥胖喘呈现出严重的非2型炎症.
- 与肥胖相关的脂质变化可能通过免疫调节驱动喘病原体.
研究的目的:
- 在肥胖喘中特征化甘油脂.
- 调查特定脂质的作用,如溶解酸丁胆 (LPC) 18:2,在免疫反应中.
主要方法:
- 在肥胖和正常体重的喘患者中,血清葡萄糖脂的脂质分析.
- 在饮食诱导的肥胖小鼠中使用了一种室内灰尘引发的喘模型.
- 在试验室和体内评估了素胆 (LPC) 18: 2 对T辅助细胞17 (Th17) 的影响.
主要成果:
- 肥胖性喘表现出明显的葡萄糖脂特征,显著降低LPC 18:2.
- 肥胖的喘小鼠表现出恶化的气道炎症和Th17极化.
- 外源性LPC 18:2加剧了炎症并促进了Th17分化,在肥胖小鼠中增加了T细胞的吸收.
结论:
- LPC 18:2 作为一种代谢调节剂,将肥胖,脂质失调和喘中的 Th17 扭曲炎症联系起来.
- 准LPC 18:2通路为肥胖喘提供了潜在的治疗策略.
更多相关视频
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
07:46Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation
Published on: April 3, 2017
相关概念视频
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Asthma-III: Symptoms and Complications
Classification of Asthma
